|Systematic (IUPAC) name|
|Routes||Oral, topical (eye drops)|
|Mol. mass||388.88 g/mol|
|(what is this?)|
Bepotastine (Talion) is a 2nd-generation antihistamine. It was approved in Japan for use in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. Senju, in turn, has granted the United States rights for the ophthalmic preparation to ISTA Pharmaceuticals, Inc., a specialty pharmaceutical company located in Irvine, CA.
- H. Takahashi, A. Ishida-Yamamoto, H. Iizuka (September 2004). "Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance". Clinical and Experimental Dermatology 29: 526–532. doi:10.1111/j.1365-2230.2004.01618.x.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|